Shalby Ltd (SHALBY) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Shalby Ltd on NSE and BSE, with an AI summary of each filing.
Disclosure under Regulation 30(5) of SEBI (LODR) Regulations
Others (Uncategorized) · 05 Nov 2026, 12:15 am
Shalby Updates Authorized KMP List Following Tushar Shah's Board Appointment Shalby Limited announced that its Board of Directors, at a meeting held on 3rd Nov'26, updated the authorization list of Key Managerial Personnel (KMPs) under Regulation 30(5) of SEBI LODR Regulations. Following the appointment of Mr. Tushar Shah as Executive Director, his designation has been revised to Executive Director & Company Secretary. The overall list of authorized KMPs remains unchanged, comprising CMD Dr. Vikram Shah, CFO Mr. Amit Kumar, President Mr. Shanay Shah, and Mr. Tushar Shah to determine materiality and execute stock exchange disclosures.
Audio recording for earnings conference call for Q2 FY 2026-27
Audio / Video · 04 Nov 2026, 11:42 pm
Shalby Limited Releases Audio Recording for Q2 FY27 Earnings Call Shalby Limited has made available the audio recording of its Q2 FY27 earnings conference call held on 4th Nov'26 at 4:00 PM IST. The disclosure, submitted in compliance with Regulations 30 and 46(2) of SEBI LODR, provides market participants access to the quarterly performance discussion via an official web link hosted on the company's portal.
Investor Presentation for the quarter ended September 30, 2026
Investor Presentation · 04 Nov 2026, 1:20 am
Shalby Limited Reports Q2 FY27 Financial Results with Steady Revenue Expansion Shalby Limited posted consolidated revenue of ₹3,182 mn in Q2 FY27, rising 9.8% YoY, while EBITDA grew 0.8% YoY to ₹464 mn with a 14.6% margin. Consolidated PAT rose 8.3% YoY to ₹79 mn, and annualized ROCE stood at 6.6%. On a standalone basis, revenue rose 9.1% YoY to ₹2,506 mn and PAT surged 19.0% YoY to ₹235 mn. Operational performance improved with total surgery count expanding 14.3% YoY to 8,618, ARPOB increasing 4.4% to ₹42,581, and hospital occupancy reaching 52%.
Appointment of Executive Director for a term of five years
Change in Management · 04 Nov 2026, 12:28 am
Shalby Appoints Tushar Shah as Executive Director for Five-Year Term Shalby Limited's Board of Directors approved the appointment of Mr. Tushar Shah (DIN: 06739455) as an Additional Director designated as Executive Director for a five-year term effective 3rd Nov'26, subject to shareholder approval via postal ballot. Mr. Shah, currently serving as Vice President & Company Secretary, possesses over 23 years of experience across corporate governance, legal affairs, M&A, and finance. He has no familial relationships with existing Directors or Key Managerial Personnel and is not debarred by SEBI or any regulatory authority.
Financial Results for the quarter and half year ended September 30, 2026
Financial Result · 04 Nov 2026, 12:25 am
Shalby Limited Q2 FY27 Financial Results and Board Appointments Summary Shalby reported consolidated revenue of ₹3,131.73M for the quarter ended 30th Sep'26, up 9.72% YoY from ₹2,854.32M, while net profit rose 8.35% YoY to ₹78.86M. On a standalone basis, revenue reached ₹2,453.19M with a net profit of ₹235.04M. Healthcare services generated ₹2,832.08M in quarterly revenue, while implant manufacturing contributed ₹299.65M. Additionally, the board approved the appointments of Mr. Shanay Vikram Shah as Whole-Time Director and Mr. Tushar Shah as Executive Director for five-year terms, subject to shareholder approval via postal ballot.
Shalby Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Outcome · 03 Nov 2026, 11:42 pm
Shalby Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million) ■ Revenue: 3,132 (+9.7% YoY | -5.4% QoQ) ■ EBITDA: 414 (-0.5% YoY | -0.5% QoQ) ■ EBITDA Margin (%): 13.2 (-136 bps YoY | +66 bps QoQ) ■ PAT: 82.8 (-1.3% YoY | -23.7% QoQ) ■ EPS (INR): 0.73 (+7.4% YoY | -25.5% QoQ) Shalby Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million) Segmental Performance Healthcare Services ■ Revenue: 2,832 (+12.1% YoY | -1.9% QoQ) ■ EBIT: 281 (+9.8% YoY | -9.8% QoQ) ■ EBIT Margin (%): 9.9 (-21 bps YoY | -87 bps QoQ) Manufacturing & Trading of Implants ■ Revenue: 300 (-8.8% YoY | -29.3% QoQ) ■ EBIT: -116 (-78.5% YoY | -1.4% QoQ) ■ EBIT Margin (%): -38.8 (-1900 bps YoY | -1177 bps QoQ)
Intimation u/r. 30 of SEBI LODR
Others (Uncategorized) · 29 Oct 2026, 12:10 am
Shalby Hospital Jabalpur Resumes Full Operations Following Regulatory Approval Shalby Limited announced that its Jabalpur hospital has resumed full operations following approval from the Chief Medical and Health Officer (CMHO), Jabalpur, on 28th Oct'26. The authority permitted normal healthcare services, including patient admissions on the previously affected floor, after the company completed necessary renovation work and implemented required safety measures. With the CMHO expressing satisfaction over compliance with stipulated terms, the facility is now entirely operational. The company reported no quantifiable financial impact from the event.
Schedule of Earnings Conference Call to discuss Q2FY2027 earnings
Intimation · 04 Nov 2026, 4:00 pm
Shalby Schedules Q2FY27 Earnings Conference Call for 4th Nov'26 Shalby Limited will host an earnings conference call on 4th Nov'26 at 4:00 PM IST to discuss its financial performance for Q2FY27. Organized by Elara Securities, the call will feature senior management, including Chairman and Managing Director Dr. Vikram Shah, President Shanay Shah, COO Dr. Nishita Shukla, and CFO Amit Kumar. Key dial-in numbers include universal access lines (+91 22 6280 1146 / +91 22 7115 8047) alongside international toll-free options for participants across the US, UK, Singapore, Hong Kong, and Australia.
SHALBY LIMITED has informed the Exchange about Board Meeting to be held on 03-Nov-2026 to consider and approve the Quarterly Unaudited Financial results of the Company for the period ended September 2026 and Other business.
Intimation · 03 Nov 2026, 5:30 am
To consider and approve the financial results for the period ended September 30, 2026 and other business matters
Intimation · 03 Nov 2026, 5:30 am
Shalby Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 ,inter alia, to consider and approve Board Meeting Intimation
Intimation · 03 Nov 2026, 5:30 am
Shalby Schedules Board Meeting on 3rd Nov'26 for Q2 Results Shalby Limited has scheduled its Board of Directors meeting for 3rd Nov'26 to consider and approve the standalone and consolidated unaudited financial results for the quarter and half-year ended 30th Sep'26. Additionally, the trading window for dealing in company equity shares has been closed for designated insiders starting 1st Oct'26 and will remain shut until 48 hours following the public announcement of the financial results.
Intimation u/r. 30 of SEBI LODR
Others (Uncategorized) · 17 Oct 2026, 8:38 pm
Shalby Resumes Normal Operations at Jabalpur Hospital Following Regulatory Clearance Shalby Limited received approval on 17th Oct'26 from the Chief Medical and Health Officer, Jabalpur, withdrawing the registration suspension of its Jabalpur hospital. The facility is permitted to resume regular healthcare services, including patient admissions, following a temporary suspension triggered by a minor fire on 11th Oct'26. The specific affected floor will remain non-operational pending renovation, reassessment, and final regulatory clearance, while the company reported no quantifiable monetary impact on its financial or operational activities.
Intimation u/r. 30 of SEBI LODR
Others (Uncategorized) · 15 Oct 2026, 12:14 am
Shalby Hospital Jabalpur Registration Suspended Following Minor Fire Incident Shalby Limited announced that the registration of its Jabalpur hospital unit has been suspended by the Chief Medical and Health Officer on 13th Oct'26, pending reassessment and submission of prescribed fire and electrical safety audit reports. The action follows a minor fire on 11th Oct'26 triggered by a reported mobile phone blast, which resulted in zero casualties. The suspension temporarily halts new patient admissions while safety audits are underway for restoration. Shalby stated the financial impact is not expected to be material to the company.
Cessation of Mr. Shanay Vikram Shah as Additional Director designated as Whole-time Director of the Company w.e.f. September 10, 2026
Change in Management · 12 Sept 2026, 8:39 pm
Shalby Shareholders Reject Appointment of Shanay Vikram Shah as Whole-Time Director Shalby Limited announced that shareholders rejected ordinary resolutions for appointing Mr. Shanay Vikram Shah as Director and Whole-time Director at the 22nd AGM held on 10th Sep'26, as per voting results declared on 11th Sep'26. Consequently, Mr. Shah automatically ceased to hold office as Additional Director (Whole-time Director) effective 10th Sep'26. However, he will continue to serve as President of the company.
Scrutinizer report of Annual General Meeting held on September 10, 2026 and voting results.
Annual General Meeting · 11 Sept 2026, 10:39 pm
Outcome and Proceeding of 22nd Annual General Meeting held on 10th September 2026
Annual General Meeting · 11 Sept 2026, 12:07 am
Weblink letter to Shareholders is atttached herewith
Annual General Meeting · 20 Aug 2026, 6:22 pm
Shalby Limited Announces 22nd AGM and FY26 Annual Report Details Shalby Limited's 22nd Annual General Meeting (AGM) is scheduled for 10th Sep'26 at 4:00 PM IST via video conference. The company has released its FY 2025-26 Annual Report, available on its website. Remote e-voting is provided for shareholders to cast votes on all resolutions. The e-voting period runs from 5th Sep'26 (9:00 AM IST) to 9th Sep'26 (5:00 PM IST). The cut-off date to determine shareholder eligibility for remote e-voting is 3rd Sep'26. Shareholders can also vote during the AGM.
Transcript of Earnings Call held on August 13, 2026
Transcript · 19 Aug 2026, 11:47 pm
Resignation of Mr. Deepak Anand, CEO of Shalby Medtech Limited, a wholly-owned subsidiary (Senior Management)
Change in Management · 18 Aug 2026, 8:13 pm
Shalby: CEO of Subsidiary Shalby Medtech Resigns Mr. Deepak Anand, CEO of wholly-owned subsidiary Shalby Medtech Limited, has resigned effective 04 Sep'26. The resignation, submitted on 18 Aug'26, is cited for personal reasons related to moving abroad. The company confirmed no other material reasons for the departure. This change impacts senior management within the Shalby group.
BRSR Report for FY 2025-26
Others (Uncategorized) · 17 Aug 2026, 11:31 pm
Shalby Limited: Key Insights from FY26 Business Responsibility and Sustainability Report Shalby Limited's FY26 sustainability report highlights key operational metrics and ESG initiatives. Total energy consumption declined 15.6% YoY to 61.96 TJ, improving energy intensity by 18.4%. However, water consumption increased 28.7% YoY to 342,268 kL, driven by operational expansion. Related party purchases were 31.48% of total purchases, up from 26.34%. Permanent employee turnover rose to 35.99% from 35.45% in FY25. The company reported zero sexual harassment complaints and two discrimination complaints (both resolved). CSR spend for FY26 was ₹32.18 million on a turnover of ₹8,985.57 million.
Annual Report FY 2025-26
Others (Uncategorized) · 17 Aug 2026, 10:49 pm
Audio Recording for Investor Con-Call for Unaudited Financials Results for QFY27
Audio / Video · 13 Aug 2026, 6:29 pm
Shalby Limited: Audio Recording for Q1 FY 2027 Earnings Call Released Shalby Limited has released the audio recording of its Q1 FY 2027 earnings conference call, held on 13 Aug'26. This is a standard disclosure under SEBI LODR regulations. The recording provides qualitative insights into the company's performance for the quarter ended 30 Jun'26, management commentary on the results, and the future outlook discussed with analysts. The filing itself contains no financial data, only the link to access the call audio.
Investor Presentation
Investor Presentation · 13 Aug 2026, 1:09 am
Shalby Q1 FY27: Consolidated Revenue Growth with Margin Compression Shalby Limited reported Q1 FY27 consolidated revenue of ₹3,386 mn, up 11.6% YoY, while PAT grew 36.7% YoY to ₹105 mn. However, EBITDA was flat at ₹490 mn (0.9% YoY growth), with the margin contracting to 14.5% from 16.0% in Q1 FY26. PBT declined 13.1% YoY to ₹197 mn. The hospital business, contributing 78% of revenue, saw occupancy rise to 51% from 45% YoY. The MedTech (implant) division posted strong 53% YoY revenue growth, though its EBITDA remains marginal at ₹1.6 mn.
Grant of ESOP under Shalby Ltd Employee Stock Options Scheme-2021
Others (Uncategorized) · 13 Aug 2026, 12:58 am
Shalby Grants 15,000 ESOPs with a ₹100 Exercise Price Shalby's Nomination and Remuneration Committee approved the grant of 15,000 Employee Stock Options on 12 Aug'26 under its ESOP Scheme 2021. Each option is convertible into one equity share (face value ₹10) and has been granted from the pool of lapsed options. The exercise price is fixed at ₹100 per option. Options will vest after two years from the grant date and can be exercised within one year from vesting. The grant will not increase share capital as shares are sourced from the secondary market.
Appointment of Mr. Shanay Vikram Shah as additional Director Designated as Whole-Time Director of the Company w.e.f. August 12, 2026.
Change in Management · 13 Aug 2026, 12:46 am
Shalby Appoints Shanay Vikram Shah as Whole-Time Director Shalby Limited's board has appointed Mr. Shanay Vikram Shah as an Additional Director, designated as Whole-Time Director and Key Managerial Personnel, effective 12 Aug'26 for a five-year term. Mr. Shah, son of Chairman & MD Dr. Vikram I. Shah, is a promoter with over a decade of healthcare experience, including roles in strategy and international business. A CFA charterholder, his appointment is subject to shareholder approval at the AGM on 10 Sep'26, signaling a key move in management succession and strategy execution.